I cannot imagine anyone would want Tysabri to fail, except investors who are doing stock options, and investors in competitive companies perhaps.

And the reverse is true too. That investors, and Directors of a Pharma will downplay (or even hide) information that detracts from the perception of their drug as Safe and as Effective.